Loading…
Cardioprotective effects of (E)-4-hydroxy-N′-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide: a newly synthesized coumarin hydrazone against isoproterenol-induced myocardial infarction in a rat model
The current study was carried out to evaluate the effect of pretreatment and co-treatment with a newly synthesized coumarin hydrazone, (E)-4-hydroxy-N′-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide (hereinafter EK6), against isoproterenol-induced myocardial infarction in rats. Changes...
Saved in:
| Published in: | Canadian journal of physiology and pharmacology 2019-10, Vol.97 (10), p.989-998 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c365t-67f717be789901882ab64c9fede03371b55a268b1f21baa72482bb0e11f72db3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c365t-67f717be789901882ab64c9fede03371b55a268b1f21baa72482bb0e11f72db3 |
| container_end_page | 998 |
| container_issue | 10 |
| container_start_page | 989 |
| container_title | Canadian journal of physiology and pharmacology |
| container_volume | 97 |
| creator | Ghazouani, Lakhdar Khdhiri, Emna Elmufti, Afoua Feriani, Anouar Tir, Meriam Baaziz, Intissar Hajji, Raouf Ben Mansour, Hedi Ammar, Houcine Abid, Souhir Mnafgui, Kais |
| description | The current study was carried out to evaluate the effect of pretreatment and co-treatment with a newly synthesized coumarin hydrazone, (E)-4-hydroxy-N′-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide (hereinafter EK6), against isoproterenol-induced myocardial infarction in rats. Changes in biochemistry, cardiac biomarkers, electrocardiography, and histopathology after treatment with EK6 or acenocoumarol (Sintrom) were studied. Animals were randomly divided into 4 groups: vehicle control (C), isoproterenol + Sintrom (ISO + Sin), isoproterenol + EK6 (ISO + EK6), and isoproterenol (ISO). Myocardial infarction was induced by subcutaneous ISO administration at a dose of 85 mg·kg
–1
·day
–1
with a drug-free interval of 24 h on days 6 and 7. Treatment with ISO led to significant elevation (p < 0.05) in serum levels of cardiac injury biomarkers, namely cardiac troponin-T, lactate dehydrogenase, creatine kinase-MB, alanine aminotransferase, and aspartate aminotransferase compared with levels in the vehicle control. A change in the lipid profile was also observed as a significant increase in total cholesterol and triglycerides. Furthermore, ISO caused significant alterations in the electrocardiogram pattern, including significant ST-segment elevation, significant decreased R wave amplitude, and significant increase in heart rate (16%) as well as marked changes in the histopathology of the heart tissue. Pretreatment and co-treatment with newly synthesized coumarin hydrazone restored all ISO-induced biochemical, lipid, cardiac, and histopathological changes in rats with myocardial infarction. |
| doi_str_mv | 10.1139/cjpp-2019-0085 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2282453311</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2282453311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-67f717be789901882ab64c9fede03371b55a268b1f21baa72482bb0e11f72db3</originalsourceid><addsrcrecordid>eNqFkb2O1DAUhS0EYoeBlhJZopkpvPgnPw4dGi0s0gqa7RCKHOea8SixBzuBzVQ8077LvgBPgkMWChoqX9_73aOjexB6zug5Y6J6pQ_HI-GUVYRSmT9AK8ZpTso8Yw_RiqYeyTjjZ-hJjIf0LaSQj9GZYFmR5Vyu0N1Ohdb6Y_AD6MF-AwzGpCpib_DmYksysp_a4G8m8uHnj1uyYWQjiL_xRFySBtzJfzKf9T74HhzhZOq2MOynzrbgYPt7Pq-rU2q8xgo7-N5NOE5u2EO0J2ix9mOvgnV44bwDrL4o6-KAbVx8BXC-I9a1o04L_eT17Fl12DqjQnLtXSqTelAD7n0L3VP0yKguwrP7d42u315c7y7J1cd373dvrogWRT6QojQlKxsoZVVRJiVXTZHpykALVIiSNXmueCEbZjhrlCp5JnnTUGDMlLxtxBptFtlk8-sIcah7GzV0nXLgx1hzLnmWC5GSWqOX_6AHPwaXzCWqKpiguRSJOl8oHXyMAUx9DDadZ6oZree86znves67nvNOCy_uZcemh_Yv_ifgBLAFcEEHiJDutf-f6C_vgrup</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2296130583</pqid></control><display><type>article</type><title>Cardioprotective effects of (E)-4-hydroxy-N′-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide: a newly synthesized coumarin hydrazone against isoproterenol-induced myocardial infarction in a rat model</title><source>SPORTDiscus with Full Text</source><creator>Ghazouani, Lakhdar ; Khdhiri, Emna ; Elmufti, Afoua ; Feriani, Anouar ; Tir, Meriam ; Baaziz, Intissar ; Hajji, Raouf ; Ben Mansour, Hedi ; Ammar, Houcine ; Abid, Souhir ; Mnafgui, Kais</creator><creatorcontrib>Ghazouani, Lakhdar ; Khdhiri, Emna ; Elmufti, Afoua ; Feriani, Anouar ; Tir, Meriam ; Baaziz, Intissar ; Hajji, Raouf ; Ben Mansour, Hedi ; Ammar, Houcine ; Abid, Souhir ; Mnafgui, Kais</creatorcontrib><description>The current study was carried out to evaluate the effect of pretreatment and co-treatment with a newly synthesized coumarin hydrazone, (E)-4-hydroxy-N′-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide (hereinafter EK6), against isoproterenol-induced myocardial infarction in rats. Changes in biochemistry, cardiac biomarkers, electrocardiography, and histopathology after treatment with EK6 or acenocoumarol (Sintrom) were studied. Animals were randomly divided into 4 groups: vehicle control (C), isoproterenol + Sintrom (ISO + Sin), isoproterenol + EK6 (ISO + EK6), and isoproterenol (ISO). Myocardial infarction was induced by subcutaneous ISO administration at a dose of 85 mg·kg
–1
·day
–1
with a drug-free interval of 24 h on days 6 and 7. Treatment with ISO led to significant elevation (p < 0.05) in serum levels of cardiac injury biomarkers, namely cardiac troponin-T, lactate dehydrogenase, creatine kinase-MB, alanine aminotransferase, and aspartate aminotransferase compared with levels in the vehicle control. A change in the lipid profile was also observed as a significant increase in total cholesterol and triglycerides. Furthermore, ISO caused significant alterations in the electrocardiogram pattern, including significant ST-segment elevation, significant decreased R wave amplitude, and significant increase in heart rate (16%) as well as marked changes in the histopathology of the heart tissue. Pretreatment and co-treatment with newly synthesized coumarin hydrazone restored all ISO-induced biochemical, lipid, cardiac, and histopathological changes in rats with myocardial infarction.</description><identifier>ISSN: 0008-4212</identifier><identifier>EISSN: 1205-7541</identifier><identifier>DOI: 10.1139/cjpp-2019-0085</identifier><identifier>PMID: 31464528</identifier><language>eng</language><publisher>Canada: NRC Research Press</publisher><subject>Alanine ; Alanine transaminase ; Animals ; Aspartate aminotransferase ; Benzopyrans - administration & dosage ; Benzopyrans - chemical synthesis ; Biochemistry ; Biomarkers ; Biomarkers - analysis ; Calcium-binding protein ; cardioprotection ; Cardiotonic Agents - administration & dosage ; Cardiotonic Agents - chemical synthesis ; Cholesterol ; Coumarin ; coumarin derivative ; Coumarins - administration & dosage ; Coumarins - chemical synthesis ; Creatine ; Creatine kinase ; Disease Models, Animal ; dérivé de la coumarine ; ECG ; EKG ; Electrocardiography ; Heart - drug effects ; Heart attacks ; Heart rate ; Heart Rate - drug effects ; Histopathology ; Humans ; Hydrazones ; Hydrazones - administration & dosage ; Hydrazones - chemical synthesis ; infarctus du myocarde ; Isoproterenol ; Isoproterenol - toxicity ; isoprotérénol ; L-Lactate dehydrogenase ; Lactic acid ; Lipids ; Male ; Medical research ; Myocardial infarction ; Myocardial Infarction - chemically induced ; Myocardial Infarction - diagnosis ; Myocardial Infarction - drug therapy ; Myocardium - pathology ; Pharmacology ; Physiology ; Rats ; Rats, Wistar ; Rodents ; Serum levels ; Studies ; Treatment Outcome ; Triglycerides ; Troponin</subject><ispartof>Canadian journal of physiology and pharmacology, 2019-10, Vol.97 (10), p.989-998</ispartof><rights>2019 Published by NRC Research Press</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-67f717be789901882ab64c9fede03371b55a268b1f21baa72482bb0e11f72db3</citedby><cites>FETCH-LOGICAL-c365t-67f717be789901882ab64c9fede03371b55a268b1f21baa72482bb0e11f72db3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31464528$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ghazouani, Lakhdar</creatorcontrib><creatorcontrib>Khdhiri, Emna</creatorcontrib><creatorcontrib>Elmufti, Afoua</creatorcontrib><creatorcontrib>Feriani, Anouar</creatorcontrib><creatorcontrib>Tir, Meriam</creatorcontrib><creatorcontrib>Baaziz, Intissar</creatorcontrib><creatorcontrib>Hajji, Raouf</creatorcontrib><creatorcontrib>Ben Mansour, Hedi</creatorcontrib><creatorcontrib>Ammar, Houcine</creatorcontrib><creatorcontrib>Abid, Souhir</creatorcontrib><creatorcontrib>Mnafgui, Kais</creatorcontrib><title>Cardioprotective effects of (E)-4-hydroxy-N′-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide: a newly synthesized coumarin hydrazone against isoproterenol-induced myocardial infarction in a rat model</title><title>Canadian journal of physiology and pharmacology</title><addtitle>Can J Physiol Pharmacol</addtitle><description>The current study was carried out to evaluate the effect of pretreatment and co-treatment with a newly synthesized coumarin hydrazone, (E)-4-hydroxy-N′-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide (hereinafter EK6), against isoproterenol-induced myocardial infarction in rats. Changes in biochemistry, cardiac biomarkers, electrocardiography, and histopathology after treatment with EK6 or acenocoumarol (Sintrom) were studied. Animals were randomly divided into 4 groups: vehicle control (C), isoproterenol + Sintrom (ISO + Sin), isoproterenol + EK6 (ISO + EK6), and isoproterenol (ISO). Myocardial infarction was induced by subcutaneous ISO administration at a dose of 85 mg·kg
–1
·day
–1
with a drug-free interval of 24 h on days 6 and 7. Treatment with ISO led to significant elevation (p < 0.05) in serum levels of cardiac injury biomarkers, namely cardiac troponin-T, lactate dehydrogenase, creatine kinase-MB, alanine aminotransferase, and aspartate aminotransferase compared with levels in the vehicle control. A change in the lipid profile was also observed as a significant increase in total cholesterol and triglycerides. Furthermore, ISO caused significant alterations in the electrocardiogram pattern, including significant ST-segment elevation, significant decreased R wave amplitude, and significant increase in heart rate (16%) as well as marked changes in the histopathology of the heart tissue. Pretreatment and co-treatment with newly synthesized coumarin hydrazone restored all ISO-induced biochemical, lipid, cardiac, and histopathological changes in rats with myocardial infarction.</description><subject>Alanine</subject><subject>Alanine transaminase</subject><subject>Animals</subject><subject>Aspartate aminotransferase</subject><subject>Benzopyrans - administration & dosage</subject><subject>Benzopyrans - chemical synthesis</subject><subject>Biochemistry</subject><subject>Biomarkers</subject><subject>Biomarkers - analysis</subject><subject>Calcium-binding protein</subject><subject>cardioprotection</subject><subject>Cardiotonic Agents - administration & dosage</subject><subject>Cardiotonic Agents - chemical synthesis</subject><subject>Cholesterol</subject><subject>Coumarin</subject><subject>coumarin derivative</subject><subject>Coumarins - administration & dosage</subject><subject>Coumarins - chemical synthesis</subject><subject>Creatine</subject><subject>Creatine kinase</subject><subject>Disease Models, Animal</subject><subject>dérivé de la coumarine</subject><subject>ECG</subject><subject>EKG</subject><subject>Electrocardiography</subject><subject>Heart - drug effects</subject><subject>Heart attacks</subject><subject>Heart rate</subject><subject>Heart Rate - drug effects</subject><subject>Histopathology</subject><subject>Humans</subject><subject>Hydrazones</subject><subject>Hydrazones - administration & dosage</subject><subject>Hydrazones - chemical synthesis</subject><subject>infarctus du myocarde</subject><subject>Isoproterenol</subject><subject>Isoproterenol - toxicity</subject><subject>isoprotérénol</subject><subject>L-Lactate dehydrogenase</subject><subject>Lactic acid</subject><subject>Lipids</subject><subject>Male</subject><subject>Medical research</subject><subject>Myocardial infarction</subject><subject>Myocardial Infarction - chemically induced</subject><subject>Myocardial Infarction - diagnosis</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardium - pathology</subject><subject>Pharmacology</subject><subject>Physiology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Rodents</subject><subject>Serum levels</subject><subject>Studies</subject><subject>Treatment Outcome</subject><subject>Triglycerides</subject><subject>Troponin</subject><issn>0008-4212</issn><issn>1205-7541</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqFkb2O1DAUhS0EYoeBlhJZopkpvPgnPw4dGi0s0gqa7RCKHOea8SixBzuBzVQ8077LvgBPgkMWChoqX9_73aOjexB6zug5Y6J6pQ_HI-GUVYRSmT9AK8ZpTso8Yw_RiqYeyTjjZ-hJjIf0LaSQj9GZYFmR5Vyu0N1Ohdb6Y_AD6MF-AwzGpCpib_DmYksysp_a4G8m8uHnj1uyYWQjiL_xRFySBtzJfzKf9T74HhzhZOq2MOynzrbgYPt7Pq-rU2q8xgo7-N5NOE5u2EO0J2ix9mOvgnV44bwDrL4o6-KAbVx8BXC-I9a1o04L_eT17Fl12DqjQnLtXSqTelAD7n0L3VP0yKguwrP7d42u315c7y7J1cd373dvrogWRT6QojQlKxsoZVVRJiVXTZHpykALVIiSNXmueCEbZjhrlCp5JnnTUGDMlLxtxBptFtlk8-sIcah7GzV0nXLgx1hzLnmWC5GSWqOX_6AHPwaXzCWqKpiguRSJOl8oHXyMAUx9DDadZ6oZree86znves67nvNOCy_uZcemh_Yv_ifgBLAFcEEHiJDutf-f6C_vgrup</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Ghazouani, Lakhdar</creator><creator>Khdhiri, Emna</creator><creator>Elmufti, Afoua</creator><creator>Feriani, Anouar</creator><creator>Tir, Meriam</creator><creator>Baaziz, Intissar</creator><creator>Hajji, Raouf</creator><creator>Ben Mansour, Hedi</creator><creator>Ammar, Houcine</creator><creator>Abid, Souhir</creator><creator>Mnafgui, Kais</creator><general>NRC Research Press</general><general>Canadian Science Publishing NRC Research Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20191001</creationdate><title>Cardioprotective effects of (E)-4-hydroxy-N′-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide: a newly synthesized coumarin hydrazone against isoproterenol-induced myocardial infarction in a rat model</title><author>Ghazouani, Lakhdar ; Khdhiri, Emna ; Elmufti, Afoua ; Feriani, Anouar ; Tir, Meriam ; Baaziz, Intissar ; Hajji, Raouf ; Ben Mansour, Hedi ; Ammar, Houcine ; Abid, Souhir ; Mnafgui, Kais</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-67f717be789901882ab64c9fede03371b55a268b1f21baa72482bb0e11f72db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Alanine</topic><topic>Alanine transaminase</topic><topic>Animals</topic><topic>Aspartate aminotransferase</topic><topic>Benzopyrans - administration & dosage</topic><topic>Benzopyrans - chemical synthesis</topic><topic>Biochemistry</topic><topic>Biomarkers</topic><topic>Biomarkers - analysis</topic><topic>Calcium-binding protein</topic><topic>cardioprotection</topic><topic>Cardiotonic Agents - administration & dosage</topic><topic>Cardiotonic Agents - chemical synthesis</topic><topic>Cholesterol</topic><topic>Coumarin</topic><topic>coumarin derivative</topic><topic>Coumarins - administration & dosage</topic><topic>Coumarins - chemical synthesis</topic><topic>Creatine</topic><topic>Creatine kinase</topic><topic>Disease Models, Animal</topic><topic>dérivé de la coumarine</topic><topic>ECG</topic><topic>EKG</topic><topic>Electrocardiography</topic><topic>Heart - drug effects</topic><topic>Heart attacks</topic><topic>Heart rate</topic><topic>Heart Rate - drug effects</topic><topic>Histopathology</topic><topic>Humans</topic><topic>Hydrazones</topic><topic>Hydrazones - administration & dosage</topic><topic>Hydrazones - chemical synthesis</topic><topic>infarctus du myocarde</topic><topic>Isoproterenol</topic><topic>Isoproterenol - toxicity</topic><topic>isoprotérénol</topic><topic>L-Lactate dehydrogenase</topic><topic>Lactic acid</topic><topic>Lipids</topic><topic>Male</topic><topic>Medical research</topic><topic>Myocardial infarction</topic><topic>Myocardial Infarction - chemically induced</topic><topic>Myocardial Infarction - diagnosis</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardium - pathology</topic><topic>Pharmacology</topic><topic>Physiology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Rodents</topic><topic>Serum levels</topic><topic>Studies</topic><topic>Treatment Outcome</topic><topic>Triglycerides</topic><topic>Troponin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghazouani, Lakhdar</creatorcontrib><creatorcontrib>Khdhiri, Emna</creatorcontrib><creatorcontrib>Elmufti, Afoua</creatorcontrib><creatorcontrib>Feriani, Anouar</creatorcontrib><creatorcontrib>Tir, Meriam</creatorcontrib><creatorcontrib>Baaziz, Intissar</creatorcontrib><creatorcontrib>Hajji, Raouf</creatorcontrib><creatorcontrib>Ben Mansour, Hedi</creatorcontrib><creatorcontrib>Ammar, Houcine</creatorcontrib><creatorcontrib>Abid, Souhir</creatorcontrib><creatorcontrib>Mnafgui, Kais</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Canadian journal of physiology and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghazouani, Lakhdar</au><au>Khdhiri, Emna</au><au>Elmufti, Afoua</au><au>Feriani, Anouar</au><au>Tir, Meriam</au><au>Baaziz, Intissar</au><au>Hajji, Raouf</au><au>Ben Mansour, Hedi</au><au>Ammar, Houcine</au><au>Abid, Souhir</au><au>Mnafgui, Kais</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardioprotective effects of (E)-4-hydroxy-N′-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide: a newly synthesized coumarin hydrazone against isoproterenol-induced myocardial infarction in a rat model</atitle><jtitle>Canadian journal of physiology and pharmacology</jtitle><addtitle>Can J Physiol Pharmacol</addtitle><date>2019-10-01</date><risdate>2019</risdate><volume>97</volume><issue>10</issue><spage>989</spage><epage>998</epage><pages>989-998</pages><issn>0008-4212</issn><eissn>1205-7541</eissn><abstract>The current study was carried out to evaluate the effect of pretreatment and co-treatment with a newly synthesized coumarin hydrazone, (E)-4-hydroxy-N′-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide (hereinafter EK6), against isoproterenol-induced myocardial infarction in rats. Changes in biochemistry, cardiac biomarkers, electrocardiography, and histopathology after treatment with EK6 or acenocoumarol (Sintrom) were studied. Animals were randomly divided into 4 groups: vehicle control (C), isoproterenol + Sintrom (ISO + Sin), isoproterenol + EK6 (ISO + EK6), and isoproterenol (ISO). Myocardial infarction was induced by subcutaneous ISO administration at a dose of 85 mg·kg
–1
·day
–1
with a drug-free interval of 24 h on days 6 and 7. Treatment with ISO led to significant elevation (p < 0.05) in serum levels of cardiac injury biomarkers, namely cardiac troponin-T, lactate dehydrogenase, creatine kinase-MB, alanine aminotransferase, and aspartate aminotransferase compared with levels in the vehicle control. A change in the lipid profile was also observed as a significant increase in total cholesterol and triglycerides. Furthermore, ISO caused significant alterations in the electrocardiogram pattern, including significant ST-segment elevation, significant decreased R wave amplitude, and significant increase in heart rate (16%) as well as marked changes in the histopathology of the heart tissue. Pretreatment and co-treatment with newly synthesized coumarin hydrazone restored all ISO-induced biochemical, lipid, cardiac, and histopathological changes in rats with myocardial infarction.</abstract><cop>Canada</cop><pub>NRC Research Press</pub><pmid>31464528</pmid><doi>10.1139/cjpp-2019-0085</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-4212 |
| ispartof | Canadian journal of physiology and pharmacology, 2019-10, Vol.97 (10), p.989-998 |
| issn | 0008-4212 1205-7541 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2282453311 |
| source | SPORTDiscus with Full Text |
| subjects | Alanine Alanine transaminase Animals Aspartate aminotransferase Benzopyrans - administration & dosage Benzopyrans - chemical synthesis Biochemistry Biomarkers Biomarkers - analysis Calcium-binding protein cardioprotection Cardiotonic Agents - administration & dosage Cardiotonic Agents - chemical synthesis Cholesterol Coumarin coumarin derivative Coumarins - administration & dosage Coumarins - chemical synthesis Creatine Creatine kinase Disease Models, Animal dérivé de la coumarine ECG EKG Electrocardiography Heart - drug effects Heart attacks Heart rate Heart Rate - drug effects Histopathology Humans Hydrazones Hydrazones - administration & dosage Hydrazones - chemical synthesis infarctus du myocarde Isoproterenol Isoproterenol - toxicity isoprotérénol L-Lactate dehydrogenase Lactic acid Lipids Male Medical research Myocardial infarction Myocardial Infarction - chemically induced Myocardial Infarction - diagnosis Myocardial Infarction - drug therapy Myocardium - pathology Pharmacology Physiology Rats Rats, Wistar Rodents Serum levels Studies Treatment Outcome Triglycerides Troponin |
| title | Cardioprotective effects of (E)-4-hydroxy-N′-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide: a newly synthesized coumarin hydrazone against isoproterenol-induced myocardial infarction in a rat model |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T14%3A51%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardioprotective%20effects%20of%20(E)-4-hydroxy-N%E2%80%B2-(1-(3-oxo-3H-benzo%5Bf%5Dchromen-2-yl)ethylidene)benzohydrazide:%20a%20newly%20synthesized%20coumarin%20hydrazone%20against%20isoproterenol-induced%20myocardial%20infarction%20in%20a%20rat%20model&rft.jtitle=Canadian%20journal%20of%20physiology%20and%20pharmacology&rft.au=Ghazouani,%20Lakhdar&rft.date=2019-10-01&rft.volume=97&rft.issue=10&rft.spage=989&rft.epage=998&rft.pages=989-998&rft.issn=0008-4212&rft.eissn=1205-7541&rft_id=info:doi/10.1139/cjpp-2019-0085&rft_dat=%3Cproquest_cross%3E2282453311%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c365t-67f717be789901882ab64c9fede03371b55a268b1f21baa72482bb0e11f72db3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2296130583&rft_id=info:pmid/31464528&rfr_iscdi=true |